Efficient prime editing in mouse brain, liver and heart with dual AAVs

[1]  Weihui Xu,et al.  Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas , 2023, The Journal of experimental medicine.

[2]  S. Yao,et al.  Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration , 2023, Signal Transduction and Targeted Therapy.

[3]  O. Abudayyeh,et al.  Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases , 2022, Nature Biotechnology.

[4]  E. Dolgin,et al.  Verve takes base editors into humans , 2022, Nature Biotechnology.

[5]  Tony P. Huang,et al.  Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors , 2022, Nature Biomedical Engineering.

[6]  R. Samulski,et al.  Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’? , 2022, Expert opinion on biological therapy.

[7]  M. Kopf,et al.  In vivo prime editing of a metabolic liver disease in mice , 2022, Science Translational Medicine.

[8]  Xingxu Huang,et al.  Genomic and Transcriptomic Analyses of Prime Editing Guide RNA-Independent Off-Target Effects by Prime Editors. , 2022, The CRISPR journal.

[9]  M. Isalan,et al.  Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings , 2022, Frontiers in Medicine.

[10]  M. Packer,et al.  Evaluation of Cytosine Base Editing and Adenine Base Editing as a Potential Treatment for Alpha-1 Antitrypsin Deficiency. , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  David R. Liu,et al.  Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins , 2022, Cell.

[12]  S. Wolfe,et al.  A flexible split prime editor using truncated reverse transcriptase improves dual AAV delivery in mouse liver. , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  David R. Liu,et al.  Programmable deletion, replacement, integration, and inversion of large DNA sequences with twin prime editing , 2021, Nature Biotechnology.

[14]  R. Bak,et al.  A truncated reverse transcriptase enhances prime editing by split AAV vectors , 2021, bioRxiv.

[15]  David R. Liu,et al.  Enhanced prime editing systems by manipulating cellular determinants of editing outcomes , 2021, Cell.

[16]  J. Loizou,et al.  Prime editing efficiency and fidelity are enhanced in the absence of mismatch repair , 2021, bioRxiv.

[17]  David R. Liu,et al.  In vivo somatic cell base editing and prime editing. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Chang Sik Cho,et al.  Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases , 2021, Nature Biomedical Engineering.

[19]  Simon P. Shen,et al.  Engineered pegRNAs improve prime editing efficiency , 2021, Nature Biotechnology.

[20]  H. Clevers,et al.  Evaluating CRISPR-based prime editing for cancer modeling and CFTR repair in organoids , 2021, Life Science Alliance.

[21]  Junjiu Huang,et al.  Dual-AAV delivering split prime editor system for in vivo genome editing. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Qiang Sun,et al.  Modeling a cataract disorder in mice with prime editing , 2021, Molecular therapy. Nucleic acids.

[23]  J. Seong,et al.  Targeted mutagenesis in mouse cells and embryos using an enhanced prime editor , 2021, Genome biology.

[24]  D. Weissman,et al.  In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels , 2021, Nature Biotechnology.

[25]  Nicole M. Gaudelli,et al.  In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates , 2021, Nature.

[26]  Kunling Chen,et al.  Genome-wide specificity of prime editors in plants , 2021, Nature Biotechnology.

[27]  S. Bae,et al.  Comprehensive analysis of prime editing outcomes in human embryonic stem cells , 2021, bioRxiv.

[28]  Gregory A. Newby,et al.  Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression , 2021, Genome Biology.

[29]  M. Boerries,et al.  Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. , 2021, Cell stem cell.

[30]  Johannes C. M. van der Loo,et al.  The clinical landscape for AAV gene therapies , 2021, Nature Reviews Drug Discovery.

[31]  T. Flotte,et al.  Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice , 2020, Nature Communications.

[32]  David R. Liu,et al.  In Vivo Base Editing Rescues Hutchinson-Gilford Progeria Syndrome in Mice , 2020, Nature.

[33]  C. Zaidman,et al.  Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. , 2020, The Journal of pediatrics.

[34]  B. Rodríguez-Santiago,et al.  Heterozygous APOE Christchurch in familial Alzheimer’s disease without mutations in other Mendelian genes , 2020, Neuropathology and applied neurobiology.

[35]  Yong-Sam Kim,et al.  Unbiased investigation of specificities of prime editing systems in human cells , 2020, Nucleic acids research.

[36]  N. Paulk.  Gene Therapy: It Is Time to Talk about High-Dose AAV , 2020 .

[37]  J. Bennett,et al.  Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV , 2020, Molecular Therapy.

[38]  Cheng-Zhong Zhang,et al.  Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing , 2020, Nature Genetics.

[39]  David R. Liu,et al.  Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors , 2020, Nature Biotechnology.

[40]  M. Mokry,et al.  Prime editing for functional repair in patient-derived disease models , 2020, Nature Communications.

[41]  Ruochi Zhang,et al.  CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity , 2020, Nature Biotechnology.

[42]  K. Niakan,et al.  Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos , 2020, Proceedings of the National Academy of Sciences.

[43]  Yulin Chen,et al.  Efficient generation of mouse models with the prime editing system , 2020, Cell Discovery.

[44]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[45]  David R. Liu,et al.  Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses , 2019, Nature Biomedical Engineering.

[46]  D. Larrey,et al.  Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation , 2019, Front. Pharmacol..

[47]  David R. Liu,et al.  Search-and-replace genome editing without double-strand breaks or donor DNA , 2019, Nature.

[48]  Justin S. Sanchez,et al.  Resistance to autosomal dominant Alzheimer’s in an APOE3-Christchurch homozygote: a case report , 2019, Nature Medicine.

[49]  W. Stanford,et al.  The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Matthew C. Canver,et al.  CRISPResso2 provides accurate and rapid genome editing sequence analysis , 2019, Nature Biotechnology.

[51]  Lihua Julie Zhu,et al.  Adenine base editing in an adult mouse model of tyrosinemia , 2019, Nature Biomedical Engineering.

[52]  Christine L. Boutros,et al.  Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids , 2019, bioRxiv.

[53]  Klaus N. Lovendahl,et al.  Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors , 2018, Nature Communications.

[54]  Martin J. Aryee,et al.  Defining CRISPR–Cas9 genome-wide nuclease activities with CIRCLE-seq , 2018, Nature Protocols.

[55]  David R. Liu,et al.  Base editing: precision chemistry on the genome and transcriptome of living cells , 2018, Nature Reviews Genetics.

[56]  M. Robinson,et al.  Treatment of a metabolic liver disease by in vivo genome base editing in adult mice , 2018, Nature Medicine.

[57]  A. Bradley,et al.  Erratum: Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements , 2018, Nature Biotechnology.

[58]  J. Taipale,et al.  CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response , 2018, Nature Medicine.

[59]  P. Thakore,et al.  RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors , 2018, Nature Communications.

[60]  Morgan L. Maeder,et al.  UDiTaS™, a genome editing detection method for indels and genome rearrangements , 2018, BMC Genomics.

[61]  James M. Wilson,et al.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. , 2018, Human gene therapy.

[62]  W. Strohl,et al.  Adeno-Associated Virus (AAV) as a Vector for Gene Therapy , 2017, BioDrugs.

[63]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[64]  J. Prieto,et al.  Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. , 2016, Journal of hepatology.

[65]  Joana A. Vidigal,et al.  Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries , 2015, Nature Communications.

[66]  Wolfgang Wurst,et al.  Development of an intein-mediated split–Cas9 system for gene therapy , 2015, Nucleic acids research.

[67]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[68]  J. Mendell,et al.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[70]  Feng Zhang,et al.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.

[71]  Jun-Hyeok Choi,et al.  Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons , 2014, Molecular Brain.

[72]  Edith T. Lopez,et al.  Mismatch Repair Genes Mlh1 and Mlh3 Modify CAG Instability in Huntington's Disease Mice: Genome-Wide and Candidate Approaches , 2013, PLoS genetics.

[73]  S. Smirnakis,et al.  Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo , 2013, The European journal of neuroscience.

[74]  L. Bernier,et al.  Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. , 2011, Clinical chemistry.

[75]  C. Mueller,et al.  Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  M. Ehlers,et al.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. , 2011, Human gene therapy.

[77]  Guoping Fan,et al.  Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons , 2010, Nature Neuroscience.

[78]  Joachim Zettler,et al.  The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans‐splicing reaction , 2009, FEBS letters.

[79]  A. Marais,et al.  Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population , 2006 .

[80]  B. Rehermann,et al.  The liver as an immunological organ , 2006, Hepatology.

[81]  James M. Wilson,et al.  Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice , 2005, Gene Therapy.

[82]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[83]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[84]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Michael L. Kotewicz,et al.  Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity , 1988, Nucleic Acids Res..

[86]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[87]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.